FDA supplemental approval: Oxycodone AND Acetaminophen (REMS)

AI Summary

This is a U.S. FDA supplemental approval action dated 18 June 2026 for a Risk Evaluation and Mitigation Strategy (REMS) governing the oxycodone-acetaminophen fixed-dose combination. The approval applies to four tablet formulations (2.5 mg, 5 mg, 7.5 mg, and 10 mg oxycodone hydrochloride, each with 325 mg acetaminophen). No clinical trial results, efficacy data, or safety findings are reported in this regulatory record.

Plain-language summary

FDA supplemental approval of a Risk Evaluation and Mitigation Strategy (REMS) for an existing oxycodone-acetaminophen combination product; this is a regulatory action, not a clinical trial, and does not report efficacy or safety data.

Study design

As stated by the source record.

Reported figures

Quoted from the source exactly as published.

Clinical bottom line

This regulatory action establishes mandatory REMS requirements for the combination product but does not provide clinical evidence of efficacy or new safety data. Clinicians should consult the approved REMS labeling and distribution requirements to understand prescribing and dispensing obligations.

Caveats

• This record does not contain clinical trial results, efficacy data, or comparative safety outcomes
• The source does not report the rationale for REMS approval or the specific REMS requirements imposed
• No information on patient populations, indications, or prior clinical evidence supporting the approval
• Record does not specify whether this is a new REMS or modification of an existing one

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.